The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

Laura Davisson is an obesity medicine doctor and professor at West Virginia University, but a growing part of her job is not ...

The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs ...

Weight loss injections work by making you feel fuller and less hungry. There are plenty of weight loss medication options to ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

A new study to be presented at the SLEEP 2025 annual meeting found that sleep medicine professionals favor continuous ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Related Aging causes more sleep disruptions, but some tips help Delays in dreaming may be linked to Alzheimer's risk FDA approves weight-loss drug Zepbound to treat sleep apnea "Obstructive sleep ...